# Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

> **NCT05999812** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 22 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** all trans Retinoic Acid
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05999812
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-19
- **Primary completion:** 2026-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05999812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05999812, "Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05999812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*